AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$THC

Romo Tammy sold (to issuer) $86K of THC

Romo Tammy sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · Romo Tammy
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides ownership-change information only; it does not include new company fundamentals or external catalysts.

02

Market read

Traders may monitor for sentiment effects, but the filing lacks fundamental drivers, making it more of a positioning/flow datapoint than a catalyst.

03

What to watch

Code D (sale to issuer) and absence of a 10b5-1 plan detail suggest the transaction may be mechanical; without additional context, directional inference is weak.

Relevance 6/10Timing: Disclosure filed 2026-05-26 for a 2026-05-22 transaction; any market read-through would be short-lived.

Background

The article is an SEC Form 4 insider transaction filing for Tenet Healthcare director Romo Tammy.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Romo Tammy sold 493 shares to the issuer for $85,673.54 at $173.78/share, disclosed via SEC Form 4.

Expected impact

Low probability of sustained price move; any reaction is likely brief and sentiment-neutral.

Evidence & confidence

The filing is a routine insider transaction disclosure, with no earnings/guidance, deal, regulatory, or litigation information provided.

Market effects

Sector

Minimal; insider Form 4s without fundamental updates rarely change sector risk pricing.

Regional

None indicated; transaction is company-specific and not tied to broader regional developments.

Global

None indicated; no international or cross-border catalyst mentioned.

Counterpoint

What could challenge this read

If investors treat any insider selling as a signal, THC could see short-term negative sentiment despite the sale-to-issuer code D.

Key entities

  • issuer
    Tenet Healthcare Corp

    Subject of the SEC Form 4 insider transaction; director sold shares to the issuer (code D).

  • director
    Romo Tammy

    Director who sold 493 shares to the issuer on 2026-05-22.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

THC insider trading history →

Related articles

OCT 5
$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

simplywall.st2 min
SEP 30
$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

theglobeandmail.com2 min
SEP 26
$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

insidermonkey.com3 min
SEP 20
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

simplywall.st3 min
SEP 9
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

simplywall.st2 min